It is my firm belief that the more involved the patient, their family, and caregivers, the better the outcome for the patient. We built DrOwl as a simple-to-use technology to increase the patient’s engagement in their own healthcare.

ALBUQUERQUE, N.M. (PRWEB)
May 12, 2020

DrOwl, a medical technology platform built on patented technology, announced today the launch of a new platform designed to allow Medicare and Medicaid patients to access, organize, search, and share their digital medical records on demand.

Most people have medical records in numerous hospitals, doctors’ offices, and health clinics. These “traditional”, compartmentalized medical record systems, silo the information away from the patient. Gaining access to these records is often difficult, and sharing information was challenging, until now.

The HIPAA-compliant DrOwl platform is offering a free tool for CMS (Medicare/Medicaid) patients to help understand their medical records. Every CMS (Medicare/Medicaid) Patient can sign in to DrOwl for free and bring in their medical records. DrOwl combines the patient’s medical record data, with proprietary AI and machine learning, to create a unique Patient Snapshot, as well as a Patient Portal which is in easy-to-understand language personalized to each patient’s medical conditions. A Personal Health Search Engine is also created for the patient to search the information in their patient portal that is unique to them. Medicare/Medicaid patients can easily read and research their medical conditions and medications in a physician-approved, trusted environment.

Patients can easily share their DrOwl patient portal with doctors, caregivers, or family members. Family members can help participate in the care of their loved ones and understand their conditions and medications in a new way.

“Being a caregiver for my mom for many years, I have a deep understanding of the challenges that patients and their caregivers face every day when it comes to accessing and understanding medical records and health conditions. DrOwl was created to give people control over their medical records and an easy way to help them understand their conditions,” said Arvind Raichur, CEO, and Co-Founder of DrOwl.

DrOwl is also rolling out telemedicine services in select areas. But the DrOwl Telemedicine platform is different from what has traditionally existed in telemedicine platforms. Patients can “chat in-app” with medical providers or participate in a video call with a physician with the click of a button, in real-time. The DrOwl telemedicine providers have access to the patient’s medical records on DrOwl including the Patient Snapshot, Patient Portal, and Personal Health Search Engine. This access to the medical records of the patients allows the DrOwl Telemedicine providers a clear snapshot of the patient’s medical history. This can lead to more efficient medical care.

Users of DrOwl can involve their loved ones in their care in a new way. Patients can add caregivers or family members to their telemedicine visits, as needed, so that the people who help to take care of them can be a part of important medical conversations, regardless of their location or time zone.

DrOwl users will have ongoing access to 100’s of physicians, including infectious disease specialists, hospitalists, generalists, and nurses, beginning with areas in Florida, with other locations coming online very shortly.

The platform also syncs with known wearable health technologies (e.g. Fitbit, Apple Health, etc.) and updates the Patient Portal for things like heart rate, steps, and more. This helps add valuable information to the patient’s medical history.

Dr. Krishan Nagda, MD, the President of DrOwl, said, “It is my firm belief that the more involved the patient, their family, and caregivers, the better the outcome for the patient. We built DrOwl as a simple-to-use technology to increase the patient’s engagement in their own healthcare. When patients are informed and educated about their health, they have the power to make more informed decisions.”

The technology also includes a tool for users to understand their risk factors for COVID-19. Users can see if they are in a group that needs to take extra precautions during outbreaks of infectious diseases.

To find out more, go to DrOwl.com or download it for free from the iTunes or Google Play app stores.

About DrOwl

DrOwl is a medical platform built on patented technology, that provides a safe place to store your medical records. It was built to store, organize, search, and share your digital medical records on demand.

Once a user securely stores their medical records, DrOwl uses AI and machine learning to provide users with a Patient Portal based on the Patient’s health records that include trusted, doctor-approved sources of information that is customized for each user and makes their medical information easier to understand. DrOwl users can also share their customized Patient Portal with caregivers or family members to include them in the patient’s healthcare decisions. Users can initiate telehealth sessions and allow their caregivers or family members to join in the secure telemedicine video call.

DrOwl provides a free electronic screening solution to help protect businesses. DrOwl’s free screening tools allows businesses to screen their employees, vendors, and visitors in order to keep their workforces and facilities as safe as possible during a difficult period.

Share article on social media or email:

Cecelia Health

Right now, we need to make sure that anyone who can’t get to their doctor can still get support, and we know Cecelia can fill that gap.

NEW YORK (PRWEB)
May 12, 2020

Cecelia Health is providing essential clinical support to people of all ages living with Type 1 and Type 2 diabetes around the country in response to challenges resulting from the COVID-19 pandemic. In partnership with the Helmsley Charitable Trust, Cecelia Health’s virtual care is an invaluable alternative to in-person visits with endocrinologists and other clinical staff for actively and successfully managing diabetes.

“Cecelia Health has an army of Certified Diabetes Care and Education Specialists (CDCESs) providing remote telehealth support to both adults and children living with insulin-dependent diabetes. Right now, we need to make sure that anyone who can’t get to their doctor can still get support, and we know Cecelia can fill that gap,” said David Panzirer, Trustee of the Helmsley Charitable Trust.

Nationwide, over 50 universities and hospitals are receiving funding from Helmsley for their diabetes clinics to help them through the COVID-19 crisis. In addition to financial support, a subset of these clinics will have access to Cecelia Health’s CDCESs to assist both patients and clinicians with providing a spectrum of support to people in managing their insulin-dependent diabetes to ease the daily burden and help improve outcomes, including:

• 
  Increasing success with using technologies like continuous glucose monitors (CGM) or blood glucose meters (BGM), or insulin pumps,
• Helping people with diabetes prepare for scheduled telemedicine visits, including uploading their CGM and insulin data to allow easy review by clinic staff,
• Providing support and education to children and parents and caregivers of children living with Type 1 diabetes,
• Assessing possible dosage and titration changes and facilitating follow up with endocrinologists if needed,
• Support for making small yet significant behavior or lifestyle changes, and
• Lending an ear at a moment when mental health is on the line for everyone, and especially for people living with increased risk of COVID-19 due to their diabetes.

“Cecelia Health’s CDCESs augment our team’s efforts to reach out to our patients, provide training and education, and prepare them for telemedicine visits. This is a tremendous help as we try to work with as many patients as possible during our rapid transition to telemedicine necessitated by COVID-19, said Dr. Ruth Weinstock, Founder and Medical Director of the Joslin Diabetes Center at SUNY Upstate Medical University, Syracuse.” Cecelia Health’s CDCES team is providing personalized and compassionate care to our patients, and we are all grateful for the added bandwidth during this challenging time.”

CDCESs will also help educate patients on resources for discounted or free medication and diabetes supplies and facilitate prior authorizations and letters of medical necessity.

“The COVID-19 pandemic has created additional complexity for people with diabetes on top of their everyday challenges they face. As an example, patients who rely on access to their providers and clinical teams for their medications, care, education and diabetes management now are not able to get those vital services. In partnership with the Helmsley Charitable Trust, we are grateful to provide our services to people living with diabetes during this difficult time” said Cecelia Health CEO and Founder, David Weingard.

About Cecelia Health

Cecelia Health’s mission is to transform and improve the lives of people living with chronic conditions worldwide. Cecelia Health has a proven track record of driving improved clinical outcomes and return on investment for customers. The Cecelia Health clinical team is comprised of nurses, dietitians, exercise physiologists, pharmacists, and social workers who are passionate about empowering people with chronic conditions to live rich, healthy and fulfilling lives. Cecelia Health partners with ACOs seeking to improve quality measures, and pharmaceutical and medical device companies seeking to improve adherence. Cecelia Health has also engaged in numerous joint initiatives with the JDRF, American Diabetes Association, the Diabetes Research Institute, the Association of Diabetes Care & Education Specialists, and The Helmsley Charitable Trust. Through their dedicated COVID-19 Resource Center. Cecelia Health is providing the latest information on how to best cope with this pandemic outbreak.

Share article on social media or email:

Xtalks Life Science Webinars

Trials that are targeting a Q3 or Q4 2020 start could accelerate the start-up period by activating all sites prior to First Person In (FPI), enabling a large proportion to start screening and enrolling simultaneously once the hold is lifted.

TORONTO (PRWEB)
May 12, 2020

The COVID-19 pandemic has brought unprecedented challenges in clinical development. Travel restrictions, social distancing and the fear of contracting the disease are impeding conventional trial conduct. Typically, routine patient and monitoring visits to healthcare facilities are now the exception, study coordinators and site staff have increased demands on their time and, in some cases, layoffs have rendered some sites incapable of continuing as usual. To help keep patients safe and allow trials to progress, regulatory authorities worldwide have issued guidance for industry, investigators and institutional review boards. Exceptional measures are rapidly being put in place in different countries. As a consequence, we have witnessed a range of responses from sponsors on clinical trial activity, such as delaying trial starts, halting screening/enrollment in most ongoing studies and changing Investigational Medicinal Product (IMP) distribution and site visits.

Our ability to adapt our approach in this ever-changing environment is critical and as a company Covance is at the forefront of partnering with specific vendors who are able to assist us in virtual technologies. These technologies enable virtual patient visits through telemedicine and phone interviews, shipping, storage and self-administration of IMP at patients’ homes and remote CRA monitoring visits. Trials that are targeting a Q3 or Q4 2020 start could accelerate the start-up period by activating all sites prior to First Person In (FPI), enabling a large proportion to start screening and enrolling simultaneously once the hold is lifted. These suggestions could help trials move forward in the face of quarantine and travel limitations, clinical site closures and altered supply chains.

Join our panel of experts from Covance along with Naim Alkhouri, MD, Director, Texas Metabolic Center and Texas Liver Institute Hepatologist for an informative live discussion on Thursday, May 28, 2020 at 11am EDT (4pm BST/UK).

For more information or to register for this event, visit NASH Clinical Development During the COVID-19 (Coronavirus) Pandemic.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

SPH Analytics received the 2020 Highest Client Satisfaction award for Population Health vendors for the fourth year in a row.

ALPHARETTA, Ga. (PRWEB)
May 12, 2020

SPH Analytics, a leader in healthcare quality and experience analytics, recently received the 2020 Highest Client Satisfaction award for its population health business unit from industry analyst Black Book Research. This is the fourth consecutive year that SPH Analytics received the top Population Health client satisfaction award for End-to-End Population Health Analytics Vendors, as determined by a random sample of U.S.-based healthcare organizations.

To add further momentum to its Population Health and Value Based Care efforts, SPH Analytics also announced it expanded its leadership team, adding industry veteran Kevin Weinstein as President, Population Health. Weinstein spent the last twenty years working with growth stage healthcare companies, primarily focused on technology and services supporting providers and payers. His previous experience includes leadership roles at Allscripts, ZirMed, Rise Health, Valence Health, Analyte Health, and Apervita.

“We are pleased to welcome Kevin to our Executive Leadership Team to provide focused leadership for our population health division. Our growth, innovation agenda and expanding base of clients that we serve warrants incremental executive focus on this important division of our business. Kevin joins SPH at a place in our journey where we have earned sustained, exceptional client satisfaction, and his deep industry knowledge and innovative mindset will be critical to our ability to continue to drive even greater value that we bring to our clients, ” said Amy Amick, CEO of SPH Analytics.

Amick continued, “This latest award serves as recognition of SPH Analytics’ relentless focus on our clients to help drive improved outcomes and lower costs. The most important aspiration we have for ourselves is to create great value for our clients; to be recognized year after year only further validates that we are delivering real impact and value for the providers and payers that we serve.”

“I am thrilled to join SPH’s award-winning team. SPH is a recognized leader in supporting the industry’s transition to value-based care and has proven themselves as an exceptional partner to both providers and payers as they manage the health of their respective populations,” said Weinstein. “I look forward to helping SPH continue to grow and help support the health of more than 40 million Americans.”

About Black Book Research

Black Book Research issues annual client experience, brand loyalty, and satisfaction rankings for a variety of technology and managed services fields, including ambulatory/ physician Electronic health record (EHR), Health Information Exchanges (HIE), banking, insurance, education, outsourcing and government. Black Book produces over two hundred annual market research reports focused on the healthcare technology solutions and services industry, under the names Black Book Research and Black Book Rankings.

About SPH Analytics

SPH Analytics (SPH), a leader in healthcare analytics and population health management, empowers clients to analyze and interpret their clinical, financial, and consumer experience data to maximize their performance. SPH’s Population Care™, Population Value™, and Population Engage™ solutions are built on the innovative Nexus™ Platform, providing insights and impact to integrated health networks, ACOs, hospitals, ambulatory care providers, physician groups, and health plans. SPH’s quality measure dashboards, financial risk measurement, healthcare survey and patient outreach solutions, and consulting services empower clients to meet the Triple Aim by improving population health, reducing overall cost of care, and improving the patient experience.

SPH Analytics is headquartered in metro Atlanta and has provided insights to clients for more than 35 years, serving clients in all 50 states. For more information, call 1-866-460-5681 or visit SPHAnalytics.com.

Share article on social media or email:

Singota is proud to work with Noveome in the fight against the coronavirus, especially to help the patients around the world, but also those close to home.

BLOOMINGTON, Ind. (PRWEB)
May 12, 2020

Singota Solutions has been selected to collaborate with Noveome Biotherapeutics, Inc. to manufacture the ST266 investigational drug product, a biologic being evaluated in clinical studies for its potential treatment of the severe inflammatory reaction known as Cytokine Release Syndrome (CRS), also known as the Cytokine Storm, observed in COVID-19 patients.

Singota specializes in small batch aseptic filling of high-value injectable products into vial, syringe, and cartridge formats using the robotic Vanrx SA25 Aseptic Filling Workcell. Singota will manufacture Noveome’s ST266 to be used for IV infusion in Phase I and II clinical trials. In preclinical and clinical studies, ST266 has demonstrated significant anti-inflammatory activity, which could potentially be lifesaving for patients experiencing the often-fatal CRS, a severe and systemic complication of COVID-19 that causes multi-organ damage, especially to the lungs.

“We commit to working quickly, yet carefully to get our clients’ products out to patients,” said Laura Englander, Senior Business Development and Marketing Manager. “Noveome has been a great partner for Singota. They have moved swiftly on the front-end, entrusting us to excel at our promise of adhering to their tight timeline to get this critical product ready for their patients.”

Singota will manufacture 30 mL vial fills of ST266 in June. This timeline helps Noveome in its accelerated efforts to treat patients in the clinic, which they are prepared to initiate immediately should the FDA approve its requested authorization to proceed with dosing.

In response to the collaboration, Alisa Kilgas, CEO at Singota stated, “We’re all in this together. Singota is proud to work with Noveome in the fight against the coronavirus, especially to help the patients around the world, but also those close to home.”

“Noveome is aggressively pursuing our investigational drug ST266 as an important therapeutic in the treatment of patients experiencing one of the most serious and life-threatening conditions brought about by COVID-19 infection. Singota’s application of isolators paired with single-use technologies uniquely positions them to establish GMP manufacturing in weeks as opposed to what would typically take several months. In addition to this enabling technology, the response and flexibility of the team at Singota has been exceptional in the rapid establishment of this collaboration,” said Kevin McCracken, Chief Operating Officer, Noveome Biotherapeutics, Inc.

For more information about our services, please contact Laura Englander at laura.englander@singota.com or (812) 961-1752.

About Singota Solutions

Singota Solutions is a contract development and manufacturing organization focused on moving products through the development pipeline faster—with agility, accountability, and transparency. Founded in 2006, the company is a woman-owned business operating in Bloomington, Indiana. Singota’s gloveless, robotic aseptic filling service is ideally suited for the production of clinical and niche commercial injectable products in vial, syringe, and cartridges formats. Singota also provides customized solutions for formulation development, supply chain & materials management, analytical testing, and labeling and kitting services. For more information, please visit http://www.singota.com.

About Noveome® Biotherapeutics

Based in Pittsburgh, Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome has launched a program to test its novel platform biologic, ST266, as a treatment for the severe inflammatory response seen in COVID-19 infection. ST266 is currently being evaluated in multiple indications including a Phase 1 open-label clinical trial to establish the safety of ST266 in intranasal transcribriform delivery from nose to brain and eye and a Phase 2 open-label clinical trial evaluating the efficacy of ST266 in healing persistent corneal epithelial defects (PEDs). For more information, visit http://www.noveome.com.

Share article on social media or email:

Dentist, Dr. Amir HagShenas, Offers Full Mouth Dental Implants in Los Gatos, CA

If you’re missing a number of teeth or all your teeth, full mouth dental implants may be for you.

LOS GATOS, Calif. (PRWEB)
May 12, 2020

Dr. Amir HagShenas lends his 30 years of dental experience to help patients seeking full mouth dental implants in Los Gatos, CA restore their mouth from missing teeth to a complete and beautiful smile. Full mouth dental implants are used to restore function and aesthetics to a smile that suffers from extensive tooth failure or multiple missing teeth. As a full-service dental implant practice, patients can receive all steps of their care in one convenient location at Silicon Valley Smile Solutions in San Jose, CA.

“Dental implants are basically root replacements that get embedded within the jawbone and allow you to have teeth on top of them. Those teeth get locked into the dental implants and that allows you to have a very beautiful, natural looking smile,” says Dr. HagShenas. “If you’re missing a number of teeth or all your teeth, full mouth dental implants may be for you.”

Full mouth dental implants are an advanced surgical procedure that can give patients with multiple failing or missing teeth a complete new smile. After extracting any remaining failing teeth, dental implants that mimic natural tooth roots are placed within the jawbone. This provides a strong support to hold a lifelike bridge of teeth. Full mouth dental implants replace all the teeth in the mouth and allow patients to chew, smile, speak and enjoy life as they would with healthy teeth.

The procedure typically involves the placement of four to six dental implants in each arch and utilizes cutting-edge dental technology to ensure accuracy, safety and predictability. Dr. HagShenas has invested in the latest Cone Beam CT scanner to capture highly detailed digital images of a patient’s bone, mouth and position of nerves. These images are then used to create dental implant guides which direct Dr. HagShenas to the proper position, angle and depth for each implant. Essentially, all guesswork is removed, and patients experience successful, gentle and long-lasting results.

Silicon Valley Smile Solutions is a full-service dental implant practice, which means that patients can get every step of their care in one location. Dr. HagShenas can extract failing teeth, provide bone grafting, place dental implants and restore them, all at his own practice. Patients affected by gum disease can also have their gum disease treated before receiving implant care to ensure maximum longevity of their smile.

Those interested in receiving full mouth dental implants in Los Gatos, CA or surrounding areas are encouraged to contact Silicon Valley Smile Solutions in San Jose, CA and schedule a consultation with Dr. HagShenas. The practice can be reached at http://www.svsmilesolutions.com or by calling 408-377-5134 to schedule an appointment.

About the Dentist

Silicon Valley Smile Solutions offers full-service dentistry in San Jose, CA. Dr. Amir HagShenas has been practicing dentistry for nearly 30 years. Dr. HagShenas received his doctorate in dental surgery degree from the University of Minnesota, where he has since been honored with the Irwin A. Epstein Award for Excellence in Endodontics, among other numerous accomplishments. Every year, Dr. HagShenas completes many hours of continuing education in implant and surgical dentistry, far above the requirements mandated by the Dental State Board of California. His motive: “I am committed to help my patients to receive the very best in dentistry.” Dr. HagShenas and his team at Silicon Valley Smile Solutions are dedicated to staying up-to-date on the latest dental technologies in order to provide the highest quality of care for patients undergoing treatments like full arch dental implants. Skilled in numerous areas of dental treatments, Dr. HagShenas is particularly passionate about providing long-lasting, full arch dental implant treatments that are, in many cases, available in just one office visit. It is Dr. HagShenas’ goal to form lasting connections with every patient built on trust, partnership, and compassion. To learn more about Dr. HagShenas and the services offered at Silicon Valley Smile Solutions visit http://www.svsmilesolutions.com or call 408-377-5134 to schedule a consultation.

Share article on social media or email:

SIMPLY – Contract Modeling + Forecasting

Contract Modeling + GtN projections for New Product Launches

MORRISTOWN, N.J. (PRWEB)
May 12, 2020

Akara Group LLC’s SIMPLY – a platform that helps Life Science Manufacturers accurately and easily project contracted liabilities with payers, providers and pharmacies – now features “PRODUCT LAUNCH,” automating the development of Gross-to-Net models by projecting discounts/rebates to Commercial and Government entities, Copay and Patient Assistance Program liabilities and Part D Coverage Gap rebates. Moreover, manufacturers can compare multiple scenarios to account for varying assumptions, such as channel mix or discount rates, and project Medicare Part B ASP to assess the impact on reimbursement for physician-administered drugs. This INDUSTRY FIRST capability allows Emerging Pharma manufacturers launching their first product or mature organizations who are adding to their portfolio to eliminate time spent on developing complex models and enhance focus on strategy and analysis.

“We are often asked by manufacturer’s who are launching their 1st product to help build GtN models in Excel,” said Romit Kamdar, Co-Founder at Akara Group LLC. “We wanted to empower our clients with an easy way for them to input some assumptions and SIMPLY automates the calculations. They can also compare different scenarios to really account for market dynamics.”

“And we succeeded in making PRODUCT LAUNCH intuitive and flexible, so training and implementation can take only a few days,” added Partha Chatterjee Co-Founder at Akara Group LLC.

SIMPLY is offered as a cloud-based, Software-as-a-Service (SaaS), with a separate hosted environment for each Manufacturer. With SIMPLY’s intuitive design, Users can easily model complicated Terms & Conditions, perform deal modeling, measure contract performance, and run “What-If” analyses. Supported by insightful data visualization and reporting, Market Access and Finance professionals are empowered with powerful tools for strategic decision making.

About Akara Group LLC

Akara Group LLC is a consulting and technology company that specializes exclusively in Managed Markets Contracts & Pricing for Life Sciences manufacturers of various sizes and portfolios. Recognized as industry experts, we believe in providing thoughtful, practical solutions to our customers. To learn more about Akara Group, visit http://www.akaragroup.com

Share article on social media or email: